Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 22

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 2
Chunk 22
---
4.

Net
Loss

The
Company recognized an Operating Loss of $ 113,349 during the three months ended March 31, 2025 whereas the Company recognized an Operating
Loss of $ 101,071 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense
categories other than rent incurred during the period ended 2024 as compared to the quarter ended in 2025.

The
Company recognized an Operating Loss of $ 174,727 during the six months ended March 31, 2025 whereas the Company recognized an Operating
Loss of $ 223,853 for the same period ended 2024. The reduction in operating loss is primarily attributable to a reduction in all expense
categories other than rent incurred during the period ended 2025 as compared to the quarter ended in 2025.

Net
Loss is $ 19,354 for the three months ended March 31, 2025 as opposed to a Net Loss of $122,454 for the same period ended 2024. The difference
is primarily attributable to the recognition by the Company of a Derivative Gain of $128,963 in 2025.

Net
Loss is $ 534,739 For the six months ended March 31, 2025 as opposed to a Net Loss of $267,387 for the same period ended 2024. The difference
is primarily attributable to the recognition by the Company of a Derivative Loss of $287,053 recognized in the period ended in 2025.

  21  

Working
Capital

                   March                         September                  
                   31, 2025                      30, 2024                   
 ────────────────────────────────────────────────────────────────────────────
  Current          $                151,749      $                 143,351  
  Current                         5,867,880                      5,378,456  
  Working          $             (5,716,131      $              (5,235,105  

Working
capital deficit increased by $ 481,026 from September 30, 2024 to March 31, 2025, primarily due to increase in Derivative Liability.

                                                        Six                                                 
                                                        Months Ended                                        
                                                        March                                               
                                                        31,                                                 
                                                        2025                            2024                
  Net                                                   $                 (167,609      $         (371,658  
  cash used in operating activities                                                                         
 ─────────────────────────────────────────